Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.

Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.

Abstract: An electronic apparatus and a controlling method thereof are provided.

Abstract: Disclosed is a display apparatus. The display apparatus includes a liquid crystal panel including a plurality of subpixels, a backlight unit including a white light source and a blue light source, and a processor configured to adjust the blue light source to emit light and to adjust an aperture ratio of at least one of the plurality of subpixels based on a color temperature of the white light source and a target color temperature.

Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.

Abstract: An electronic device includes a cover glass, a back cover, a side member that surrounds a space between the cover glass and the back cover, wherein at least a portion of the side member is formed of a conductive member, a support member that is extended from the side member and includes at least one opening, a first printed circuit board that is interposed between the support member and the back cover or between the support member and the cover glass, a second printed circuit board that is interposed between the first printed circuit board and the back cover or between the first printed circuit board and the cover glass, an electrical component that is positioned on the first printed circuit board, and a wireless communication circuit that is positioned on the second printed circuit board.

Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.

Abstract: The present disclosure relates to a lighting device based on scenario-activation using a push service, and a push server, a control device and a communication device for controlling the lighting device. In one embodiment of the present disclosure, a push server for controlling a lighting device based on scenario-activation using a push service, may include: a communication unit for receiving a control message, based on a first communication protocol, from a control device and for transmitting the received control message to either a communication device or a push gateway based on the first communication protocol; a control message storage unit for storing, therein, the control message; a communication device-identification storage unit for storing, therein, identifications of communication devices to receive the control message; and, a control unit configured for controlling the communication unit, the control message storage unit, and the communication device-identification storage unit.

Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.

Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.

Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.

Abstract: The present disclosure relates to a lighting device based on scenario-activation using a push service, and a push server, a control device and a communication device for controlling the lighting device. In one embodiment of the present disclosure, a push server for controlling a lighting device based on scenario-activation using a push service, may include: a communication unit for receiving a control message, based on a first communication protocol, from a control device and for transmitting the received control message to either a communication device or a push gateway based on the first communication protocol; a control message storage unit for storing, therein, the control message; a communication device-identification storage unit for storing, therein, identifications of communication devices to receive the control message; and, a control unit configured for controlling the communication unit, the control message storage unit, and the communication device-identification storage unit.

Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.

Abstract: A method for detecting a ground fault in an inverter using leg-shunt resistors is provided. The method includes detecting output currents of three phases of the inverter, determining whether or not a voltage utilization of the inverter is not less than a preset allowable voltage level, and determining an occurrence or non-occurrence of the ground fault in the inverter.

Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.

Abstract: A transmission system of a hybrid electric vehicle may include an input shaft connected to an engine, a planetary gear set including a first rotation element operated as an output element, a second rotation element connected to the input shaft and operated as an input element, and a third rotation element operated as another output element, a first motor operably connected to the first rotation element, and selectively connected to a transmission housing, a first motor/generator configured to generate electric energy by receiving torque through the first motor shaft, a second motor shaft being a hollow shaft, disposed at a radial exterior of the first motor shaft without rotational interference with the first motor shaft, and operably connected to the third rotation element so as to receive torque of the engine, and a second motor/generator disposed on the second motor shaft and outputting torque through the second motor shaft.

Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Homer-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.